Tivic Health, BARDA discuss entolimod for acute radiation syndrome

Tivic Health (TIVC) delivered an invited presentation at a TechWatch meeting with the Biomedical Advanced Research and Development Authority on January 26, with select members of the Department of Defense, Defense Threat Reduction Agency, National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases. The company presented key clinical and manufacturing readiness data for Tivic’s Toll-like Receptor 5 agonist, Entolimod, underscoring its potential use as a radiation countermeasure, as well as progress on manufacturing readiness that has been accelerated by newly formed subsidiary Velocity Bioworks.TechWatch meetings enable BARDA and other U.S. agencies to evaluate technology and manufacturing readiness and to identify potential pathways for funding and purchasing new technologies. Monday’s meeting initiated Tivic’s discussions with the agency regarding the potential for incorporating Entolimod into the Strategic National Stockpile, with key stakeholders requesting expedited follow-up. “We appreciate the U.S. government’s interest in the differentiated properties of Entolimod compared to the other drugs already stockpiled for treating ARS,” said Tivic CEO Jennifer Ernst. “We are fully committed to supporting BARDA and other agencies in their exploration of Entolimod through our upcoming engagements.”